COMPPARE

Patient accrual has closed. Now, it’s up to participants to continue to complete COMPPARE’s Quality of Life and Side Effects Follow-up Questionnaires.

By Bob Marckini Last month, a gentleman told us, sadly, that his father had died from prostate cancer. He then admitted he’d met with his primary care doctor only sporadically over the years and, despite this, didn’t even have regular PSA tests or DREs. Further, he skipped doctors’ visits completely…

Patient Accrual Closes, Participant Surveys are Collected, and Data Analysis Begins In 2017, a research team led by Nancy Mendenhall, M.D., medical director of the UF Health Proton Therapy Institute, was awarded a five-year, $11.9 million grant from the Patient-Centered Outcomes Research Institute (PCORI) to directly compare…

Dr. Nancy Mendenhall discusses COMPPARE with the MUSC radiation oncology team. The Medical University of South Carolina, Charleston (MUSC), founded in 1824, is South Carolina’s sole integrated academic health sciences center. Similarly, MUSC’s Hollings Cancer Center, one of 71 National Cancer Institute-designated cancer centers in the nation,…

A Message from Dr. Nancy Mendenhall I am excited to share with you that on October 31, 2022, COMPPARE closed enrollment with a total of 2,524 participants (1,024 photon patients and 1,500 proton patients; 900 pragmatic, 600 randomized)! Read Dr. Mendenhall’s message.   Partner Site…

The COMPPARE Coordinating Center announced today that the study has enrolled its 1,000th photon prostate cancer patient to reach 67% of its photon cohort goal. COMPPARE Partner Site University of Maryland enrolled the 1,000th patient, followed closely by UNC REX Healthcare, Raleigh, NC, which…

A Message from Dr. Nancy Mendenhall As we near the completion of COMPPARE’s overall enrollment objective – a total of 3,000 patients – we are beginning to reflect and evaluate what we’ve learned thus far in creating and carrying out a large, multi-institutional pragmatic…

The COMPPARE Coordinating Center announced today that the study has enrolled its 1,500th proton prostate cancer patient and has closed enrollment for the proton cohort. This goal was achieved in advance of the projected completion date of July 31, 2022. The proton cohort is divided into two groups: Pragmatic and…

The COMPPARE Coordinating Center announced today that the study achieved 75% enrollment on May 3, 2022. COMPPARE realized both a remarkable overall accrual rate and a exceptional accrual rate of minorities, despite the ongoing challenges presented by COVID-19. In fact, the study stands to become a model for patient-centric clinical…

Founded in Houston, TX, in 1941, the University of Texas MD Anderson Cancer Center (MDACC) has a distinguished history as one of the nation’s original three comprehensive cancer centers designated by the National Cancer Act of 1971 and is currently one of only 51 National Cancer…